A CRISPR 2.0 pioneer, expecting credit on its own invention, is ruffled by a competitor
Last week, the genome-editing scientists behind base editing, a technology dubbed CRISPR 2.0, gathered for an update from the competition. Intellia Therapeutics, a company invested in the classic form of CRISPR, was to unveil its take on base editing, a refined approach to fixing DNA that corrects single letters of the genome without breaking
The presentation, hosted by the famed Cold Spring Harbor Laboratory, sounded familiar.
